Drug intelligence / Profile preview

NV01-062

Development stage: Preclinical
Lead developer: Neuroventi
Modality: Small Molecules
Administration: Intraperitoneal

Overview

NV01-062 is a small molecule new chemical entity (NCE) developed by Neuroventi, currently in preclinical development for the treatment of autism spectrum disorder (ASD) and depression. It functions as a dual-target modulator of the imidazoline receptor and the N-methyl-D-aspartate (NMDA) receptor. The compound is undergoing pharmacokinetic and toxicity testing to support its advancement into clinical trials. Neuroventi's approach with NV01-062 focuses on addressing the underlying neurobiological imbalances associated with social communication deficits in ASD and the symptoms of depressive disorders.

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)IR (Imidazoline receptor)

Beyond the preview

Go deeper on NV01-062.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NV01-062.

Explore the full profile